Elsilimomab (also known as B-E8) is a mouse monoclonal antibody and an immunosuppressive drug.
It (OPR-003) targets (and blocks) Interleukin-6.
It has undergone a number of early stage clinical trails, e.g. for lymphoma and myeloma.
It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.
- ^ "WHO Drug Information". "p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer"
- ^ "First Fully Human Anti-IL6 Antibody Under Development". Oct 2006.
- ^ a b Fulciniti et al.; Hideshima, T; Vermot-Desroches, C; Pozzi, S; Nanjappa, P; Shen, Z; Patel, N; Smith, ES et al. (2009). "A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma". Clinical cancer research : an official journal of the American Association for Cancer Research 15 (23): 7144–52. doi:10.1158/1078-0432.CCR-09-1483. PMC 2787636. PMID 19934301.